Published in Clin Infect Dis on September 18, 2012
Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. PLoS One (2016) 1.44
Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation. Am J Respir Crit Care Med (2016) 1.41
Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunology (2014) 0.97
Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother (2013) 0.93
Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol (2013) 0.88
Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation. Front Immunol (2015) 0.81
Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo) (2015) 0.80
Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. PLoS One (2013) 0.78
Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med (2016) 0.77
Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants. J Am Soc Nephrol (2015) 0.76
Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation. Transplantation (2016) 0.76
Cytomegalovirus Infection in Ireland: Seroprevalence, HLA Class I Alleles, and Implications. Medicine (Baltimore) (2016) 0.75
Cytomegalic hepatitis in a patient receiving omalizumab. IDCases (2016) 0.75
Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients. Curr Infect Dis Rep (2013) 0.75
Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation. Liver Transpl (2014) 0.75
Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia. Medicine (Baltimore) (2017) 0.75
Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies. Infect Chemother (2017) 0.75
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol (2007) 2.35
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2004) 2.23
Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation (2004) 2.11
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis (2010) 1.98
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 1.94
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis (2009) 1.64
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant (2005) 1.45
Foreword: Guidelines 3. Am J Transplant (2013) 1.39
Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis (2002) 1.37
A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation (2010) 1.35
Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis (2002) 1.28
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis (2012) 1.25
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis (2005) 1.14
A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant (2004) 1.09
Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol (2010) 1.09
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis (2004) 1.08
The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation (2011) 1.07
Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation (2005) 1.05
A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis (2005) 1.05
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther (2009) 1.05
A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant (2005) 1.03
Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation (2005) 1.02
Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation (2012) 1.00
A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis (2007) 1.00
Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. J Infect Dis (2003) 0.99
Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis (2003) 0.98
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet (2005) 0.98
A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant (2005) 0.98
Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J Clin Virol (2002) 0.97
Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J Clin Microbiol (2008) 0.97
A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation (2007) 0.97
An international survey of cytomegalovirus management practices in lung transplantation. Transplantation (2010) 0.97
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation (2004) 0.95
Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant (2002) 0.95
Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis (2008) 0.95
Unrecognized pretransplant and donor‐derived cryptococcal disease in organ transplant recipients. Clin Infect Dis (2010) 0.94
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother (2007) 0.94
Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis (2005) 0.93
Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation (2003) 0.93
Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis (2010) 0.93
Graphium basitruncatum fungemia in a patient with acute leukemia. J Clin Microbiol (2007) 0.93
Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis (2013) 0.92
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation (2005) 0.92
Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation (2008) 0.92
Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation (2011) 0.91
Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant (2003) 0.91
A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis (2008) 0.90
QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Rev Mol Diagn (2008) 0.89
A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant (2011) 0.89
Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation (2013) 0.88
A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis (2005) 0.87
Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant (2011) 0.87
The production of transgenic pigs for potential use in clinical xenotransplantation: microbiological evaluation. Xenotransplantation (2002) 0.86
Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant (2006) 0.85
Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med (2004) 0.85
Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant (2008) 0.84
The production of transgenic pigs for potential use in clinical xenotransplantation: baseline clinical pathology and organ size studies. Xenotransplantation (2002) 0.84
An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis (2009) 0.84
Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation (2002) 0.84
An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One (2012) 0.83
Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant (2010) 0.82
A novel model to study bacterial adherence to the transplanted airway: inhibition of Burkholderia cepacia adherence to human airway by dextran and xylitol. J Heart Lung Transplant (2004) 0.82
Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation (2012) 0.82
Long term immune responses to pandemic influenza A/H1N1 infection in solid organ transplant recipients. PLoS One (2011) 0.82
Life-threatening infection in transplant recipients. Crit Care Clin (2013) 0.82
Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am (2010) 0.82
Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant (2008) 0.81
Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Transplantation (2016) 0.81
Third-generation cephalosporin-resistant spontaneous bacterial peritonitis: a single-centre experience and summary of existing studies. Can J Gastroenterol Hepatol (2013) 0.81
Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis (2002) 0.80
Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation (2014) 0.79
Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant (2003) 0.79
Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. J Heart Lung Transplant (2009) 0.79
Cytomegalovirus prophylaxis: how long is enough? Nat Rev Nephrol (2010) 0.79
Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. Diabetes Technol Ther (2013) 0.79